Intercept Reports Additional Positive OCA Data in Patients With Bile Acid Diarrhea at Digestive Disease Week

[GlobeNewswire] – NEW YORK — Intercept Pharmaceuticals, Inc. (Intercept) today announced new OBADIAH trial results showing potential clinical benefits of obeticholic acid (OCA) for patients with bile acid diarrhea. OCA, … more

View todays social media effects on ICPT

View the latest stocks trending across Twitter. Click to view dashboard

See who Intercept is hiring next, click here to view